CA2890981C - Amide-substituted heterocyclic compounds useful as modulators of il-12, il-23 and/or ifn.alpha. responses - Google Patents

Amide-substituted heterocyclic compounds useful as modulators of il-12, il-23 and/or ifn.alpha. responses Download PDF

Info

Publication number
CA2890981C
CA2890981C CA2890981A CA2890981A CA2890981C CA 2890981 C CA2890981 C CA 2890981C CA 2890981 A CA2890981 A CA 2890981A CA 2890981 A CA2890981 A CA 2890981A CA 2890981 C CA2890981 C CA 2890981C
Authority
CA
Canada
Prior art keywords
treating
pharmaceutically acceptable
acceptable salt
medicament
manufacture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2890981A
Other languages
English (en)
French (fr)
Other versions
CA2890981A1 (en
Inventor
Ryan M. MOSLIN
David S. Weinstein
Stephen T. Wrobleski
John S. Tokarski
Amit Kumar
Douglas G. Batt
Shuqun Lin
Chunjian Liu
Steven H. Spergel
Yanlei Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49876960&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2890981(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of CA2890981A1 publication Critical patent/CA2890981A1/en
Application granted granted Critical
Publication of CA2890981C publication Critical patent/CA2890981C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epidemiology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA2890981A 2012-11-08 2013-11-07 Amide-substituted heterocyclic compounds useful as modulators of il-12, il-23 and/or ifn.alpha. responses Active CA2890981C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261723840P 2012-11-08 2012-11-08
US61/723,840 2012-11-08
PCT/US2013/068846 WO2014074661A1 (en) 2012-11-08 2013-11-07 AMIDE-SUBSTITUTED HETEROCYCLIC COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFN ALPHα RESPONSES

Publications (2)

Publication Number Publication Date
CA2890981A1 CA2890981A1 (en) 2014-05-15
CA2890981C true CA2890981C (en) 2022-07-05

Family

ID=49876960

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2890981A Active CA2890981C (en) 2012-11-08 2013-11-07 Amide-substituted heterocyclic compounds useful as modulators of il-12, il-23 and/or ifn.alpha. responses

Country Status (39)

Country Link
US (7) US9505748B2 (enExample)
EP (3) EP2922846B1 (enExample)
JP (3) JP6407159B2 (enExample)
KR (1) KR102195194B1 (enExample)
CN (1) CN104884454B (enExample)
AR (1) AR094452A1 (enExample)
AU (4) AU2013341186B2 (enExample)
BR (1) BR112015010102B1 (enExample)
CA (1) CA2890981C (enExample)
CL (1) CL2015001231A1 (enExample)
CY (3) CY1121188T1 (enExample)
DK (2) DK2922846T3 (enExample)
EA (1) EA028814B1 (enExample)
ES (2) ES2914793T3 (enExample)
FI (1) FIC20230028I1 (enExample)
FR (1) FR23C1030I2 (enExample)
HR (2) HRP20220766T1 (enExample)
HU (3) HUE041750T2 (enExample)
IL (1) IL238610A0 (enExample)
LT (3) LT2922846T (enExample)
MA (1) MA38072A1 (enExample)
MX (2) MX2015005731A (enExample)
MY (3) MY198262A (enExample)
NL (1) NL301238I2 (enExample)
NO (1) NO2023032I1 (enExample)
NZ (1) NZ708859A (enExample)
PE (1) PE20150944A1 (enExample)
PH (1) PH12015501004A1 (enExample)
PL (2) PL2922846T3 (enExample)
PT (2) PT2922846T (enExample)
RS (2) RS63328B1 (enExample)
SG (3) SG10201706897TA (enExample)
SI (2) SI3495358T1 (enExample)
SM (2) SMT201900001T1 (enExample)
TR (1) TR201820824T4 (enExample)
TW (1) TWI605041B (enExample)
UY (1) UY35126A (enExample)
WO (1) WO2014074661A1 (enExample)
ZA (1) ZA201504052B (enExample)

Families Citing this family (114)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2015005561A (es) 2012-11-08 2015-07-23 Squibb Bristol Myers Co Compuestos de pirimidina sustituidos con alquil-amida utiles en la modulacion de interleucina 12 (il-12) interleucina 23 (il-23) y/o interferon alfa (ifn alfa).
UY35126A (es) * 2012-11-08 2014-05-30 Bristol Myers Squibb Co Ojo es alfa
AR094537A1 (es) 2013-11-07 2015-08-12 Bristol Myers Squibb Co COMPUESTOS DE PIRIDILO SUSTITUIDOS CON ALQUILAMIDA ÚTILES COMO MODULADORES DE LAS RESPUESTAS DE IL-12, IL-23 Y/O IFNa
CN105992768B (zh) 2013-12-10 2018-04-20 百时美施贵宝公司 用作IL‑12、IL‑23和/或IFNα响应的调节剂的咪唑并哒嗪化合物
WO2015123453A1 (en) * 2014-02-14 2015-08-20 Portola Pharmaceuticals, Inc. Pyridazine compounds as jak inhibitors
KR102097878B1 (ko) * 2015-11-26 2020-04-06 노파르티스 아게 디아미노 피리딘 유도체
TWI825663B (zh) 2016-10-14 2023-12-11 美商林伯士拉克許米公司 Tyk2抑制劑及其用途
EP3528816A4 (en) 2016-10-21 2020-04-08 Nimbus Lakshmi, Inc. TYK2 INHIBITORS AND USES THEREOF
MA48602A (fr) * 2016-12-13 2020-03-18 Bristol Myers Squibb Co Composés hétéroaryle substitués par un amide alkyle d'oxyde de phosphine en tant que modulateurs des réponses il-12, il-23 et/ou ifn alpha
JOP20180011A1 (ar) 2017-02-16 2019-01-30 Gilead Sciences Inc مشتقات بيرولو [1، 2-b]بيريدازين
US10336752B2 (en) 2017-03-08 2019-07-02 Nimbus Lakshmi, Inc. TYK2 inhibitors, uses, and methods for production thereof
IL305615A (en) * 2017-03-30 2023-11-01 Bristol Myers Squibb Co Crystal form of -6(cyclopropanecarboxamido)-4-((-2methoxy-3-(-1methyl- 4 2, 1-1,H-triazol-3-yl)phenyl(amino)-N-)methyl-D3(pyridazine -3-carboxamide
JP7258903B2 (ja) * 2017-11-21 2023-04-17 ブリストル－マイヤーズ スクイブ カンパニー スルホンピリジンアルキルアミド置換ヘテロアリール化合物
AR117398A1 (es) 2018-03-12 2021-08-04 Abbvie Inc Inhibidores de la señalización mediada por tirosina cinasa 2
CN111936486B (zh) * 2018-03-22 2023-09-22 百时美施贵宝公司 用作IL-12、IL-23和/或IFNα响应的调节剂的包含吡啶的杂环化合物
CN118994117A (zh) * 2018-05-31 2024-11-22 百时美施贵宝公司 化合物的结晶形式
TWI898556B (zh) 2018-07-13 2025-09-21 美商基利科學股份有限公司 吡咯并[1,2-b]嗒衍生物
GB201816369D0 (en) 2018-10-08 2018-11-28 Sareum Ltd Pharmaceutical compounds
CN113271940A (zh) 2018-10-15 2021-08-17 林伯士拉克许米公司 Tyk2抑制剂和其用途
JP7631193B2 (ja) 2018-10-22 2025-02-18 アルミス インコーポレイテッド Ｔｙｋ２阻害剤およびその使用
US12240840B2 (en) * 2018-10-30 2025-03-04 Bristol-Myers Squibb Company Amide-substituted heterocyclic compounds for the treatment of conditions related to the modulation of IL-12, IL-23 and/or IFN-alpha
CN113271938A (zh) 2018-11-30 2021-08-17 林伯士拉克许米公司 Tyk2抑制剂和其用途
WO2020154474A1 (en) 2019-01-23 2020-07-30 Nimbus Lakshmi, Inc. Tyk2 inhibitors and uses thereof
WO2020156311A1 (zh) * 2019-01-28 2020-08-06 江苏豪森药业集团有限公司 一种哒嗪类衍生物抑制剂、其制备方法和应用
CN111484480B (zh) * 2019-01-29 2023-08-11 上海翰森生物医药科技有限公司 一种多环类衍生物抑制剂、其制备方法和应用
SG11202108162SA (en) * 2019-01-30 2021-08-30 Bristol Myers Squibb Co Amide-disubstituted pyridine or pyridazine compounds
US11357775B2 (en) 2019-04-30 2022-06-14 Celgene Corporation Combination therapies comprising apremilast and Tyk2 inhibitors
MX2021013317A (es) * 2019-04-30 2022-01-18 Celgene Corp Terapias de combinacion que comprenden inhibidores de apremilast y tyk2.
CN120309591A (zh) * 2019-06-12 2025-07-15 百时美施贵宝公司 化合物的结晶盐形式
WO2021011513A1 (en) 2019-07-16 2021-01-21 Bristol-Myers Squibb Company Prodrugs in the modulation of interleukin
EP4007757B1 (en) 2019-08-01 2025-09-10 Sperogenix Therapeutics Limited Heterocyclic compounds as kinase inhibitor and uses thereof
EP4027995A4 (en) 2019-09-13 2023-08-23 Nimbus Saturn, Inc. HPK1 ANTAGONISTS AND THEIR APPLICATIONS
US20230255964A1 (en) 2019-09-18 2023-08-17 Bristol-Myers Squibb Company Extended release dosage forms for tyk2 inhibitors
US20230039086A1 (en) * 2019-12-17 2023-02-09 Crystal Pharmaceutical (Suzhou) Co., Ltd. Bms-986165 crystal form, preparation method therefor and use thereof
WO2021143498A1 (zh) * 2020-01-19 2021-07-22 苏州科睿思制药有限公司 一种Deucravacitinib的晶型及其制备方法和用途
WO2021143430A1 (zh) * 2020-01-19 2021-07-22 苏州科睿思制药有限公司 一种bms-986165盐酸盐晶型及其制备方法和用途
CN115003667B (zh) * 2020-02-26 2025-04-15 百济神州有限公司 Tyk-2抑制剂
MX2022011297A (es) 2020-03-11 2022-10-07 Beijing Innocare Pharma Tech Co Ltd Compuestos heterociclicos para inhibir las actividades de tyk2.
WO2021204626A1 (en) * 2020-04-06 2021-10-14 Almirall, S.A. Aryl and heteroaryl-carboxamide substituted heteroaryl compounds as tyk2 inhibitors
GB202005114D0 (en) 2020-04-07 2020-05-20 Sareum Ltd Crystalline Forms of a Pharmaceutical Compound
CN113563309B (zh) * 2020-04-28 2024-12-13 浙江海正药业股份有限公司 吡啶类衍生物及其制备方法和用途
KR20230004771A (ko) * 2020-04-28 2023-01-06 브리스톨-마이어스 스큅 컴퍼니 Il-12, il-23 및/또는 ifn알파 조정제로서의 치환된 n-(메틸-d3)피리다진-3-카르복스아미드 또는 n-(메틸-d3)-니코틴아미드 화합물
CN113735836B (zh) * 2020-05-28 2023-05-30 江苏先声药业有限公司 哒嗪类化合物及其应用
CN113735837B (zh) * 2020-05-28 2023-09-01 江苏先声药业有限公司 哒嗪类化合物及其用途
CN113773262B (zh) * 2020-06-09 2024-08-09 江苏先声药业有限公司 哒嗪类化合物
IL299294A (en) 2020-06-22 2023-02-01 Beigene Ltd tyk-2 inhibitor
CN113968846A (zh) * 2020-07-24 2022-01-25 上海翰森生物医药科技有限公司 一种哒嗪类衍生物的盐、晶型及其制备方法和应用
CA3186000A1 (en) * 2020-07-24 2022-01-27 Shanghai Hansoh Biomedical Co., Ltd. Crystal form of pyridazine derivative free base, and preparation method therefor and use thereof
EP3944859A1 (en) 2020-07-30 2022-02-02 Assistance Publique Hôpitaux de Paris Method for treating immune toxicities induced by immune checkpoint inhibitors
CN114057651B (zh) * 2020-07-31 2025-05-27 正大天晴药业集团股份有限公司 含酰胺基的tyk2抑制剂化合物
WO2022021684A1 (zh) * 2020-07-31 2022-02-03 苏州科睿思制药有限公司 一种bms-986165盐酸盐晶型csv及其制备方法和用途
US20240325388A1 (en) * 2020-09-18 2024-10-03 Bristol-Myers Squibb Company Dosage forms for tyk2 inhibitors comprising swellable cores
CN116615200B (zh) * 2020-10-20 2025-04-29 杭州领业医药科技有限公司 哒嗪衍生物的晶型
EP4232425A4 (en) 2020-10-23 2024-07-24 Nimbus Clotho, Inc. Ctps1 inhibitors and uses thereof
CN120887875A (zh) * 2020-11-12 2025-11-04 上海睿跃生物科技有限公司 酪氨酸激酶2(tyk2)降解化合物和使用方法
TW202227430A (zh) * 2020-11-17 2022-07-16 大陸商江蘇恆瑞醫藥股份有限公司 含氮雜環類衍生物、其製備方法及其在醫藥上的應用
CN116547276A (zh) * 2020-12-08 2023-08-04 正大天晴药业集团股份有限公司 含酰胺基和杂环烷基的tyk2抑制剂化合物
JP2024505063A (ja) * 2021-01-29 2024-02-02 ブリストル－マイヤーズ スクイブ カンパニー ６－（シクロプロパンカルボキサミド）－４－（（２－メトキシ－３－（１－メチル－１Ｈ－１，２，４－トリアゾール－３－イル）フェニル）アミノ）－Ｎ－（メチル－ｄ３）ピリダジン－３－カルボキサミドの結晶形態
AU2022215844A1 (en) 2021-02-02 2023-09-14 Liminal Biosciences Limited Gpr84 antagonists and uses thereof
CN117098757A (zh) 2021-02-02 2023-11-21 里米诺生物科学有限公司 Gpr84拮抗剂和其用途
TW202233600A (zh) * 2021-02-06 2022-09-01 大陸商正大天晴藥業集團股份有限公司 含聯環的ｔｙｋ２抑制劑化合物、藥物組合物及其用途
CN114907326B (zh) * 2021-02-06 2025-02-18 正大天晴药业集团股份有限公司 含酰胺基和联环的tyk2抑制剂化合物
CN117120090A (zh) 2021-02-12 2023-11-24 林伯士萨顿公司 Hpk1拮抗剂和其用途
AU2022222470A1 (en) 2021-02-19 2023-09-21 Sudo Biosciences Limited Tyk2 inhibitors and uses thereof
WO2022175752A1 (en) 2021-02-19 2022-08-25 Sudo Biosciences Limited Tyk2 inhibitors and uses thereof
US11926625B2 (en) 2021-03-05 2024-03-12 Nimbus Saturn, Inc. HPK1 antagonists and uses thereof
JP2024510274A (ja) * 2021-03-16 2024-03-06 アンルイ バイオメディカル テクノロジー （グァンヂョウ） カンパニー リミテッド アミノヘテロアリール化合物および組成物
WO2022212181A1 (en) 2021-03-29 2022-10-06 Bristol-Myers Squibb Company Crystal forms of 6-(cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1h-1,2,4-triazol-3-yl)phenyl)amino)-n-(methyl-d3)pyridazine-3-carboxamide
EP4313989A4 (en) 2021-03-29 2025-03-05 Nimbus Saturn, Inc. HPK1 ANTAGONISTS AND USES THEREOF
US20240182429A1 (en) * 2021-03-30 2024-06-06 Zhejiang Wenda Pharma Technology Ltd. Heterocyclic compound as tyk2 pseudokinase domain inhibitor, synthetic method, and use
CN115197196B (zh) * 2021-04-06 2024-06-18 扬子江药业集团有限公司 Tyk2抑制剂及其用途
EP4319756A4 (en) 2021-04-09 2025-02-26 Nimbus Clio, Inc. CBL-B MODULATORS AND USES THEREOF
EP4335440A4 (en) * 2021-05-04 2025-05-14 Shanghai Zheye Biotechnology Co., Ltd. NITROGEN-CONTAINING HETEROCYCLIC PYRIDINE COMPOUND
US20240317718A1 (en) * 2021-05-14 2024-09-26 Bristol-Myers Squibb Company Substituted heterocyclic compounds
TW202311247A (zh) * 2021-05-14 2023-03-16 美商必治妥美雅史谷比公司 經取代之雜環化合物
US20250066322A1 (en) 2021-05-14 2025-02-27 Bristol-Myers Squibb Company Substituted heterocyclic compounds
US20240270723A1 (en) 2021-05-14 2024-08-15 Bristol-Myers Squibb Company Substituted heterocyclic compounds
WO2022253335A1 (zh) * 2021-06-02 2022-12-08 南京明德新药研发有限公司 含磺酰基的芳基类化合物及其应用
CN115466289A (zh) * 2021-06-11 2022-12-13 爱科诺生物医药(香港)有限公司 具有tyk2抑制活性的化合物，包含其的药物组合物，及其应用
BR112023026964A2 (pt) * 2021-06-22 2024-03-12 Medshine Discovery Inc Composto de sulfoximina e uso do mesmo
CN117794911A (zh) * 2021-07-15 2024-03-29 南京明德新药研发有限公司 含硫/磷的芳基类化合物及其应用
WO2023023322A1 (en) * 2021-08-20 2023-02-23 Bristol-Myers Squibb Company Crystal forms of 6-(cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1h-1,2,4-triazol-3-yl)phenyl)amino)-n-(methyl-d3)pyridazine-3-carboxamide
WO2023027948A1 (en) * 2021-08-21 2023-03-02 Relay Therapeutics, Inc. Jak2 inhibitors and methods of use thereof
EP4404930A1 (en) 2021-09-23 2024-07-31 Bristol-Myers Squibb Company Methods of treating hair-loss disorders with tyk2 inhibitors
JP2024535467A (ja) 2021-09-30 2024-09-30 ブリストル－マイヤーズ スクイブ カンパニー Ｔｙｋ２阻害剤に対する応答性を決定する方法
CN119013277A (zh) 2021-10-25 2024-11-22 凯麦拉医疗公司 Tyk2降解剂和其用途
EP4422690A1 (en) 2021-10-28 2024-09-04 Bristol-Myers Squibb Company Topical formulations of deucravacitinib
EP4441043A1 (en) 2021-12-01 2024-10-09 Teva Czech Industries s.r.o Solid state forms of deucravacitinib, deucravacitinib hcl and process for preparation of deucravacitinib and intermediates
WO2023108536A1 (en) * 2021-12-16 2023-06-22 Lynk Pharmaceuticals Co. Ltd. Tyk2 inhibitors and compositions and methods thereof
TW202339749A (zh) * 2021-12-16 2023-10-16 大陸商凌科藥業有限公司 Ｔｙｋ２抑制劑及其組合物和方法
CN116283928A (zh) * 2021-12-20 2023-06-23 艾立康药业股份有限公司 一种哒嗪类化合物、其制备方法和应用
EP4206196A1 (en) 2021-12-29 2023-07-05 Almirall S.A. Pyrimidine substituted derivatives as tyk2 inhibitors
CN116693449A (zh) 2022-03-04 2023-09-05 上海致根医药科技有限公司 用作tyk2抑制剂的化合物、其制备方法及其在医药上的应用
CN119233971A (zh) * 2022-05-31 2024-12-31 上海华汇拓医药科技有限公司 一种哒嗪类化合物、其制备方法和用途
WO2024020221A1 (en) 2022-07-21 2024-01-25 Arvinas Operations, Inc. Modulators of tyk2 proteolysis and associated methods of use
WO2024028364A1 (en) 2022-08-02 2024-02-08 Liminal Biosciences Limited Aryl-triazolyl and related gpr84 antagonists and uses thereof
IL318576A (en) 2022-08-02 2025-03-01 Liminal Biosciences Ltd Pyridoxine-substituted GPR84 antagonists and their uses
KR20250057800A (ko) 2022-08-02 2025-04-29 리미널 바이오사이언시스 리미티드 헤테로아릴 카복스아마이드 및 관련 gpr84 길항제 및 이의 용도
EP4615832A1 (en) 2022-11-08 2025-09-17 Bristol-Myers Squibb Company Substituted heterocyclic compounds
WO2024127363A1 (en) 2022-12-16 2024-06-20 Alembic Pharmaceuticals Limited Tyk2 pseudokinase ligands and uses thereof
CN116284040B (zh) * 2023-01-05 2024-05-28 华润医药研究院（深圳）有限公司 含氮杂环类化合物及其医药用途
CN120693328A (zh) * 2023-02-07 2025-09-23 浙江华海药业股份有限公司 一种哒嗪类化合物、其制备方法和用途
CN118724752B (zh) * 2023-03-29 2025-11-28 重庆博腾制药科技股份有限公司 一种酪氨酸激酶抑制剂中间体、制备方法及其应用
CN116162093B (zh) * 2023-04-25 2023-06-23 中南大学湘雅医院 一种tyk2抑制剂化合物及其用途
WO2024236491A1 (en) * 2023-05-15 2024-11-21 Glenmark Life Sciences Limited Process for the preparation of deucravacitinib, and crystalline forms thereof
CN119080742A (zh) * 2023-06-05 2024-12-06 甘莱制药有限公司 脂质合成的杂环调节剂的工业化制备
WO2024257023A1 (en) 2023-06-14 2024-12-19 Alembic Pharmaceuticals Limited Tyk2 pseudokinase ligands and uses thereof
TW202529769A (zh) 2023-09-21 2025-08-01 日商武田藥品工業股份有限公司 Ｔｙｋ２抑制劑及其用途
CN117447353A (zh) * 2023-09-21 2024-01-26 爱斯特（成都）生物制药股份有限公司 一种氘可来昔替尼中间体的制备方法
EP4538259A1 (en) 2023-10-09 2025-04-16 Farmhispania Group, S.L. Processes for the preparation of deucravacitinib
WO2025131031A1 (zh) * 2023-12-22 2025-06-26 上海奥博生物医药股份有限公司 一种TyK2抑制剂及其中间体的制备方法
WO2025186427A1 (en) 2024-03-08 2025-09-12 Curia Spain, S.A.U. Process for the preparation of deucravacitinib and intermediates thereof and method for purifying deucravacitinib
CN118593504B (zh) * 2024-06-03 2025-03-18 北京大学第三医院（北京大学第三临床医学院） 氘可来昔替尼或其盐在制备pvns药物方面的新用途
CN119059972B (zh) * 2024-08-12 2025-10-28 武汉九州钰民医药科技有限公司 一种btk抑制剂吡托布鲁替尼的合成方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1184376B1 (en) * 1999-06-09 2005-02-02 Yamanouchi Pharmaceutical Co. Ltd. Novel heterocyclic carboxamide derivatives
JP4622047B2 (ja) * 1999-06-09 2011-02-02 アステラス製薬株式会社 新規なヘテロ環カルボキサミド誘導体
AU5108000A (en) * 1999-06-10 2001-01-02 Yamanouchi Pharmaceutical Co., Ltd. Novel nitrogen-contaiing heterocyclic derivatives or salts thereof
US7273868B2 (en) 2000-04-28 2007-09-25 Tanabe Seiyaku Co., Ltd. Pyrazine derivatives
CA2356544C (en) 2000-10-03 2006-04-04 Warner-Lambert Company Pyridotriazines and pyridopyridazines
MXPA05000655A (es) 2002-07-15 2006-02-22 Harvard College Metodos y composiciones para modular el desarrollo y la funcion de las celulas t helper (th).
US7176214B2 (en) 2003-05-21 2007-02-13 Bristol-Myers Squibb Company Imidazo-fused oxazolo[4,5-β]pyridine and imidazo-fused thiazolo[4,5-β]pyridine based tricyclic compounds and pharmaceutical compositions comprising same
WO2011113802A2 (en) 2010-03-17 2011-09-22 F. Hoffmann-La Roche Ag Imidazopyridine compounds, compositions and methods of use
BR112013006016A2 (pt) 2010-09-15 2016-06-07 Hoffmann La Roche compostos de azabenzotiazol, composições e métodos de uso
KR20140009259A (ko) 2010-11-19 2014-01-22 에프. 호프만-라 로슈 아게 피라졸로피리딘 및 tyk2 억제제로서 이의 용도
JP5878178B2 (ja) * 2011-09-30 2016-03-08 大鵬薬品工業株式会社 １，２，４−トリアジン−６−カルボキサミド誘導体
WO2013104573A1 (en) * 2012-01-10 2013-07-18 F. Hoffmann-La Roche Ag Pyridazine amide compounds and their use as syk inhibitors
UY34807A (es) * 2012-05-16 2013-12-31 Novartis Ag Derivados monocíclicos de heteroarilcicloalquil- diamina
US9040530B2 (en) 2012-06-22 2015-05-26 Portola Pharmaceuticals, Inc. 1,2,4-triazine-6-carboxamide kinase inhibitors
HK1211024A1 (en) 2012-10-19 2016-05-13 霍夫曼-拉罗奇有限公司 Inhibitors of syk
BR112015010244A8 (pt) 2012-11-08 2019-10-01 Bristol Myers Squibb Co compostos de piridila substituída por alquil-amida úteis como moduladores de il-12, il-23 e/ou respostas de ifnalfa, sua composição farmacêutica e seu uso
MX2015005561A (es) 2012-11-08 2015-07-23 Squibb Bristol Myers Co Compuestos de pirimidina sustituidos con alquil-amida utiles en la modulacion de interleucina 12 (il-12) interleucina 23 (il-23) y/o interferon alfa (ifn alfa).
UY35126A (es) * 2012-11-08 2014-05-30 Bristol Myers Squibb Co Ojo es alfa
AR094537A1 (es) 2013-11-07 2015-08-12 Bristol Myers Squibb Co COMPUESTOS DE PIRIDILO SUSTITUIDOS CON ALQUILAMIDA ÚTILES COMO MODULADORES DE LAS RESPUESTAS DE IL-12, IL-23 Y/O IFNa
IL305615A (en) 2017-03-30 2023-11-01 Bristol Myers Squibb Co Crystal form of -6(cyclopropanecarboxamido)-4-((-2methoxy-3-(-1methyl- 4 2, 1-1,H-triazol-3-yl)phenyl(amino)-N-)methyl-D3(pyridazine -3-carboxamide

Also Published As

Publication number Publication date
US20220356180A1 (en) 2022-11-10
PE20150944A1 (es) 2015-06-20
US20250243193A1 (en) 2025-07-31
MA38072A1 (fr) 2016-07-29
WO2014074661A1 (en) 2014-05-15
EP2922846B1 (en) 2018-10-03
MY175448A (en) 2020-06-29
SMT201900001T1 (it) 2019-02-28
MY194668A (en) 2022-12-12
MY198262A (en) 2023-08-17
AU2018267545A1 (en) 2018-12-13
AU2020203967A1 (en) 2020-07-16
AU2017201076B2 (en) 2018-11-15
BR112015010102A2 (pt) 2017-07-11
US10526321B2 (en) 2020-01-07
ZA201504052B (en) 2017-11-29
UY35126A (es) 2014-05-30
SG10201706985UA (en) 2017-10-30
HUE059409T2 (hu) 2022-11-28
MX2020003156A (es) 2020-07-29
HK1215255A1 (en) 2016-08-19
TR201820824T4 (tr) 2019-01-21
PT3495358T (pt) 2022-06-02
CA2890981A1 (en) 2014-05-15
CN104884454B (zh) 2017-11-28
EP4071144A1 (en) 2022-10-12
PH12015501004B1 (en) 2015-07-27
LTPA2023523I1 (enExample) 2023-09-11
PL3495358T3 (pl) 2022-06-27
US10000480B2 (en) 2018-06-19
NL301238I2 (nl) 2023-10-04
US20150299183A1 (en) 2015-10-22
JP6585231B2 (ja) 2019-10-02
US9505748B2 (en) 2016-11-29
SI2922846T1 (sl) 2019-04-30
US20200071315A1 (en) 2020-03-05
SI3495358T1 (sl) 2022-06-30
MX2015005731A (es) 2015-09-16
HRP20220766T1 (hr) 2022-09-16
LT3495358T (lt) 2022-05-25
LT2922846T (lt) 2018-12-10
ES2702148T3 (es) 2019-02-27
PT2922846T (pt) 2018-12-19
SG11201503399XA (en) 2015-05-28
US20170022192A1 (en) 2017-01-26
AR094452A1 (es) 2015-08-05
NO2023032I1 (en) 2023-08-25
JP6407159B2 (ja) 2018-10-17
AU2020203967B2 (en) 2020-10-22
RS58187B1 (sr) 2019-03-29
DK3495358T3 (da) 2022-05-23
HUE041750T2 (hu) 2019-05-28
EP3495358B1 (en) 2022-04-27
CY1125220T1 (el) 2025-03-28
PL2922846T3 (pl) 2019-03-29
JP2018154636A (ja) 2018-10-04
SMT202200258T1 (it) 2022-07-21
LTC2922846I2 (enExample) 2024-10-25
FR23C1030I2 (fr) 2024-10-25
CL2015001231A1 (es) 2015-08-28
US20180265504A1 (en) 2018-09-20
EP3495358B8 (en) 2022-06-08
AU2013341186B2 (en) 2017-03-30
EA028814B1 (ru) 2018-01-31
EA201590917A1 (ru) 2015-09-30
TW201422593A (zh) 2014-06-16
AU2018267545B2 (en) 2020-04-02
AU2013341186A1 (en) 2015-07-02
SG10201706897TA (en) 2017-09-28
CY2023017I2 (el) 2024-02-16
HRP20181937T1 (hr) 2019-01-25
KR102195194B1 (ko) 2020-12-24
BR112015010102B1 (pt) 2022-02-08
HUS2300025I1 (hu) 2023-08-28
JP2020002157A (ja) 2020-01-09
FIC20230028I1 (fi) 2023-08-28
CY1121188T1 (el) 2020-05-29
NZ708859A (en) 2018-11-30
KR20150081339A (ko) 2015-07-13
PH12015501004A1 (en) 2015-07-27
ES2914793T3 (es) 2022-06-16
IL238610A0 (en) 2015-06-30
CY2023017I1 (el) 2023-11-15
FR23C1030I1 (fr) 2023-10-13
DK2922846T3 (en) 2019-01-21
RS63328B1 (sr) 2022-07-29
TWI605041B (zh) 2017-11-11
AU2017201076A1 (en) 2017-03-09
EP3495358A1 (en) 2019-06-12
US11021475B2 (en) 2021-06-01
JP2016506369A (ja) 2016-03-03
EP2922846A1 (en) 2015-09-30
USRE47929E1 (en) 2020-04-07
CN104884454A (zh) 2015-09-02

Similar Documents

Publication Publication Date Title
CA2890981C (en) Amide-substituted heterocyclic compounds useful as modulators of il-12, il-23 and/or ifn.alpha. responses
CA2930060C (en) Alkyl-amide-substituted pyridyl compounds useful as modulators of il-12, il-23 and/or ifnalpha responses
AU2013341185B2 (en) Alkyl-amide-substituted pyridyl compounds useful as modulators of IL-12, IL-23 and/or IFNalpha responses
HK40083010A (en) Amide-substituted heterocyclic compounds useful as modulators of il-12, il-23 and/or ifn alpha responses
HK40010074B (en) Amide-substituted heterocyclic compounds useful as modulators of il-12, il-23 and/or ifn alpha responses
HK40010074A (en) Amide-substituted heterocyclic compounds useful as modulators of il-12, il-23 and/or ifn alpha responses
HK1215255B (en) Amide-substituted heterocyclic compounds useful as modulators of il-12, il-23 and/or ifn-alpha
HK1226400B (en) Alkyl-amide-substituted pyridyl compounds useful as modulators of il-12, il-23 and/or ifnalpha responses

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20180927

EEER Examination request

Effective date: 20180927

EEER Examination request

Effective date: 20180927